IsoPlexis — Merger or Acquisition (January 2023)
10 slides from IsoPlexis's merger presentation, Jan 27, 2023
Slide 1: A transformational combination
A transformational combination B oerKecey uichrs Zisoplexis portfolio to ssolate, functionally ‘enabling functionalproteomics characterize, and recover ive cells (asda CELL)
Slide 2: PhenomeX: a functional cell biology company
Phenomex:aA functional cell biologycompany WHAT WE D0 HOW WE DoIT WHY ITMATTERS Enable scientists to unlock By providing a deeper Because understandingthe the potential of cell biology analysis of cell function phenome is central to all for research and clinical while preserving the live application
Slide 3: Lower-cost IsoPlexis platform to offer enhanced functionality for technology portfolio
Lower-cost IsoPlexis platformto offer enhanced functionality for technology portfolio Unique Dimension of Cell Behavior vs. FlowCytometry _ Tncessng demand of low userfor uncon setonety A isoplexis <== Unique Effortless Workflow, Throughput, Cost vs. MultiplexedProteomics Fuffling demandof proteomic
Slide 4: Significant installed base in four years
Significant installed base in four years 277 isthe ectey INSTRUMENTS IN THEFIELD Medical Centers 112 100% 79% $18.9M —orcovicensne cr >) PROTEOMICS, SEQUENCING, AND SYSTEM PATENTS.
Slide 5: Current product roadmap
Current product roadmap + #isoplexis
Slide 6: Significantly expanding customer base
Significantly expanding customerbase Berkeley Lights Customers IsoPlexis Customers Ser FOE sts GHD sa canon sas me Dt "Se zoctis
Slide 7: Combination lays a great foundation for a strong life sciences tools company
Combination lays a great foundation for a strong life sciences tools company ¥ 400+ installed instrumentbase ¥ Ability to reach Academic and Biopharma/CRO ¥ Placed in 100% of Top Pharma ‘companies across all geographies ¥ More sales & commercial supportemployees v’ Accelerated product launchtimeline
Slide 8: Cost synergies from acquisition will increase profitability and accelerate timeline to breakeven
Cost synergies from acquisition willincrease «(> profitability and accelerate timeline to breakeven General and Administrative © Cost synergies e Prioritization of High-value R&D ~$70M re cost synergies annualized by2024 © Complementary R&D Capabilities @ Marketing Resources andSales Operations Manu
Slide 9: Investment Highlights
Investment Highlights PhenomeX Platform for further consolidation in high-growth, single-cell biology tools space Expanded and balanced product portfolioat diferent price points with a focus on recuring revenue substan seale, ly expanded access to larger cell blology market, enhanced commercial jdve
Slide 10: Forward-Looking Statements
Forward-Looking Statements Certain statements in this communication regarding the proposed transaction between Berkeley Lights and IsoPlexis, the expected timetable for completing the transaction, benefits and synergies of the transaction, future opportunities for the combined company and products a